Medication Monitor

Generic Name (Trade Name—Company)
June 30, 2011


(Lazanda—Archimedes Pharma)
First nasal formulation approved


Management of breakthrough pain in adults with cancer 

This fentanyl nasal spray is indicated for adults 18 years of age and older who are already receiving opioid therapy but are tolerate to this therapy for their underlying persistent cancer pain. The nasal spray delivers fentanyl as a fine mist to the mucus membrane, with the drug rapidily being absorbed into the bloodstream. Once a dose is taken, patients must wait at least 2 hours before taking another dose. The spray will be available in the second half of this year through a Risk Evaluation and Mitigation Strategy (REMS) program intended to minimize the risk of misuse, abuse, addiction, overdose, and serious complications as a result of medication errors. Under the REMS program, pharmacies, distributors, and health providers who prescribe to outpatients are required to enroll in the program to dispense, distribute, and prescribe fentanyl spray.